Reuters: Zika vaccine race spurred by crisis and profit potential
“The race to find protection against the Zika virus is fueled by something often missing from tropical disease research: the potential for big profit. The prospect of a blockbuster vaccine against a mosquito-borne virus has accelerated the pace of development and attracted the interest of big drugmakers, including Sanofi SA, GlaxoSmithKline Plc, and Takeda Pharmaceuticals…” (Berkrot, 10/4).